TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16022747
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (1.5 g daily)
Study: 10648305
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I - Avoided positive inotropic catecholamines and vasodilators; mechanical ventilation with low tidal volumes < 8 mL/kg, duration of inspiration:expiration = 3:1, peak inspiratory pressures < 18 cm H(2)O
Study: 10648305
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II - Used positive inotropic catecholamines and vasodilators; mechanical ventilation with high tidal volumes (10‐15 mL/kg) and peak inspiratory pressures up to 50 cm H(2)O
Study: 1988778
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate 50 mg as an intramuscular depot injection every 3 weeks for 1 year
Study: 1988778
Drug: Estrogen‐progestogen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen‐progestogen therapy (2 mg 17 beta‐estradiol plus 1 mg norethisterone acetate) daily for 1 year
Study: 6216814
Drug: Manipulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulation therapy (MTG)
Study: 6216814
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CTG)
Study: 31560580
Drug: CDK4/6 inhibitor
Normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitor and an aromatase inhibitor (AI)
Study: 25491882
Drug: Nasal intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal intermittent positive pressure ventilation (NIPPV) + very early surfactant treatment
Study: 20561180
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of melatonin daily
Study: 17660178
Drug: Neomycin 0.35%/polymyxin
Normalized name: NEOMYCIN 0.35%/POLYMYXIN OPH OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin 0.35%/polymyxin B 10,000 IU/mL/hydrocortisone 1.0% (NPH)
Study: 15683857
Drug: 10% concentrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% concentrated intravenous gammaglobulin
Study: 15683857
Drug: 5% concentrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% concentrated intravenous gammaglobulin
Study: 3040815
Drug: Itraconazole 50
Normalized name: ITRACONAZOLE 50MG/5ML SOLN,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 50 mg before breakfast
Study: 3040815
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg before breakfast
Study: 3040815
Drug: Itraconazole 50
Normalized name: ITRACONAZOLE 50MG/5ML SOLN,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 50 mg with breakfast
Study: 3040815
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg with breakfast
Study: 28447203
Drug: 400 µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 µg/day folate
Study: 28447203
Drug: 800 µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 µg/day folate
Study: 22982085
Drug: Capitalization approach
Normalized name: acetaminophen / codeine phosphate Oral Suspension [Capital and Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capitalization approach (treatment matched to relative strengths)
Study: 22982085
Drug: Compensation approach
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compensation approach (treatment matched to relative deficits)
Study: 15660025
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (4‐12 mg/d)
Study: 12106837
Drug: Reperfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion therapy in AMI patients
Study: 10433575
Drug: Clarithromycin 1000
Normalized name: clarithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 1000 mg b.i.d.
Study: 1747286
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (30 ng kg‐1 min‐1)
Study: 1747286
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion during exercise
Study: 6174041
Drug: Acebutolol, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol, 300 mg three times daily
Study: 6174041
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release quinidine sulfate in identical doses
Study: 31651299
Drug: Pre-surgery physiotherapy
Normalized name: ENSURE PRE-SURGERY LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-surgery physiotherapy for 9 weeks, adherence to ≥12 treatment sessions
Study: 31651299
Drug: Pre-surgery physiotherapy
Normalized name: ENSURE PRE-SURGERY LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-surgery physiotherapy for 9 weeks, adherence to 0-11 treatment sessions
Study: 28803710
Drug: Intrathecal HPβCD
Normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal HPβCD 900 mg
Study: 28803710
Drug: Intrathecal HPβCD
Normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal HPβCD 1200 mg
Study: 28803710
Drug: Intrathecal HPβCD
Normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal HPβCD 600 or 900 mg
Study: 11802520
Drug: Zotepine 150
Normalized name: zotepine
DrugBank: Zotepine (DB09225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotepine 150 mg/day
Study: 11802520
Drug: Haloperidol 9
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol 9 mg/day
Study: 9824170
Drug: Cognitive‐behavioral group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral group treatment (CBT)
Study: 9824170
Drug: Interactional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactional group treatment (IT)
Study: 668973
Drug: triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: triamcinolone acetonide (0.25 mg/cm2 of the skin)
Study: 25851287
Drug: Antibiotics +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics + Vitamin E supplementation (intervention group; n=76)
Study: 25851287
Drug: Antibiotics (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (control group; n=76)
Study: 19360499
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational therapy with modified right half-field eye-patching for 4 weeks
Study: 19360499
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment only for 4 weeks
Study: 17433315
Drug: Metformin 2.5
Normalized name: glipizide-metformin 2.5 mg-250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 2.5 g/day
Study: 17433315
Drug: Metformin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1.5 g/day
Study: 11481350
Drug: Both sequences
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both sequences at identical irinotecan doses
Study: 3185647
Drug: Insulin-dependent diabetics
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetics with neuropathy
Study: 3185647
Drug: Insulin-dependent diabetics
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetics without neuropathy
Study: 30227980
Drug: Aerosolized lidocaine
Normalized name: Lidocaine Topical Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized lidocaine (10% solution, 70 mg) applied over larynx and trachea
Study: 30227980
Drug: Cotton swabs
Normalized name: Cotton Swabs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotton swabs impregnated with 1 ml of 20 mg lidocaine solution
Study: 25169589
Drug: Paclitaxel-coated balloon
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-coated balloon (DCB) (3 µg/mm²)
Study: 23274779
Drug: CMC/PEO gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMC/PEO gel treatment group
Study: 20953883
Drug: HMB/Glu/Arg (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB/Glu/Arg (24 g dissolved in water twice daily for 8 weeks)
Study: 14658015
Drug: perindoprilat infusion
Normalized name: perindoprilat
DrugBank: Perindoprilat (DB14213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: perindoprilat infusion
Study: 8096473
Drug: 30-min oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-min oxytocin infusion regimen
Study: 8096473
Drug: 15-min oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-min oxytocin infusion regimen
Study: 30396554
Drug: Weekly progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly progesterone vaginal ring (VR)
Study: 30396554
Drug: Daily progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily progesterone gel
Study: 27379922
Drug: Tolvaptan (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (7.5 mg) in combination with conventional diuretics (furosemide 20 mg and spironolactone 25 mg)
Study: 27379922
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (furosemide 20 mg and spironolactone 25 mg)
Study: 27379922
Drug: Tolvaptan (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (7.5 mg) in combination with conventional diuretics
Study: 21997865
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (SB) 250 mg twice daily for 5 days
Study: 20561606
Drug: Transdiagnostic Internet‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic Internet‐based cognitive behavioural treatment (iCBT) program
Study: 16938157
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg i.v.
Study: 16938157
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg i.v.
Study: 11953079
Drug: DNA immunoabsorbent
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA immunoabsorbent therapy
Study: 81588
Drug: Gamma globulin
Normalized name: Gamma globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma globulin immunotherapy
Study: 30196790
Drug: Algorithm including
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Algorithm including elevated C-reactive protein ≥30 mg/l
Study: 22104026
Drug: Local thermal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local thermal therapy with far‐infrared rays (FIR), 20 minutes per day, twice a week, for 20 sessions
Study: 22104026
Drug: Local thermal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local thermal therapy with far‐infrared rays (FIR)
Study: 3120758
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radiotherapy (45 Gy) and chemotherapy (doxorubicin and cyclophosphamide)
Study: 3120758
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radiotherapy and chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil)
Study: 22236504
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg metyrapone/20 mg oxazepam (low dose)
Study: 22236504
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg metyrapone/20 mg oxazepam (high dose)
Study: 19258546
Drug: Calcium (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (2.0 g/d)
Study: 17630547
Drug: saquinavir/ritonavir 2000/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: saquinavir/ritonavir 2000/100 mg o.d.
Study: 17630547
Drug: saquinavir/ketoconazole 2000/400
Approvals — FDA: no, EMA: no, PMDA: no
Description: saquinavir/ketoconazole 2000/400 mg o.d.
Study: 9238166
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (radiotherapy)
Study: 9238166
Drug: Cisplatin-containing chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin-containing chemotherapy
Study: 9238166
Drug: New promising
Approvals — FDA: no, EMA: no, PMDA: no
Description: New promising chemotherapy regimens and new fractionated radiation schedules
Study: 9238166
Drug: Innovative therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovative therapeutic approaches (biotherapies, recombinant cytokines, antitumoral vaccine, gene therapy)
Study: 22515282
Drug: restrictive oral
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: restrictive oral appliance (restrict‐MMOA)
Study: 22515282
Drug: free‐MMOA (full‐arch
Approvals — FDA: no, EMA: no, PMDA: no
Description: free‐MMOA (full‐arch maxillary and mandibular oral appliances with no restrictions of mandibular movements)
Study: 22515282
Drug: baseline (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: baseline (no oral appliance)
Study: 16643361
Drug: Triazolam administered
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triazolam administered orally 75 minutes prior to scheduled atrial shock delivery
Study: 8972016
Drug: US formulation
Normalized name: Semaglutide 4 MG Oral Tablet [RYBELSUS FORMULATION R2]
Approvals — FDA: no, EMA: no, PMDA: no
Description: US formulation of Hemofil-M at a dose of 50 u/kg
Study: 8972016
Drug: Spanish formulation
Normalized name: Spanish thyme oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spanish formulation of Hemofil-M at a dose of 50 u/kg
Study: 6141750
Drug: Alpha-blocker phenoxybenzamine
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blocker phenoxybenzamine (10-20 mg daily)
Study: 6141750
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alpha-blocker phenoxybenzamine (10-20 mg daily) and beta-blocker sotalol (40-80 mg daily)
Study: 27022607
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Group: 50 mg/kg MgSO4 intravenously in 150 mL saline
Study: 27022607
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) Group: 50 mg/kg MgSO4 in 30 mL saline injected intramuscularly
Study: 27022607
Drug: Control (C)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (C) Group: 30 mL saline injected intramuscularly
Study: 20576667
Drug: Neurodevelopmental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental treatment
Study: 12895267
Drug: Interferon A
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon A (10 MU IntronA/day for 2 weeks, followed by 10 MU/2 days for 12 weeks) + ribavirin (1-1.2 g/day)
Study: 12895267
Drug: Interferon B
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon B (5 MU/day for 14 weeks) + ribavirin (1-1.2 g/day)
Study: 12895267
Drug: Interferon C
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon C (5 MU/2 days for 14 weeks) + ribavirin (1-1.2 g/day)
Study: 10907971
Drug: Other dosages
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other dosages of HMG-CoA reductase inhibitors
Study: 6726981
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of activated charcoal and sorbitol
Study: 6726981
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of charcoal and cathartic
Study: 28904371
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose insulin infusion
Study: 28904371
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose hydrocortisone with high insulin
Study: 17287298
Drug: Intrabronchial administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrabronchial administration of recombinant surfactant protein C-based surfactant preparation (Venticute)
Study: 17287298
Drug: Surfactant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant treatment (Venticute)
Study: 17287298
Drug: Supplementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation of Venticute with synthetic neutral lipid preparation
Study: 8791050
Drug: Cisplatin 60
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 60 mg/m2 i.v. and epirubicin 60 mg/m2 i.v. every 3 weeks for six cycles, with estramustine phosphate at 10 mg/kg p.o. in two divided daily doses during chemotherapy and until progression.
Study: 1619006
Drug: Intranasal octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal octreotide 2000 micrograms
Study: 1619006
Drug: Intranasal octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal octreotide 1000 micrograms
Study: 1619006
Drug: Intranasal octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal octreotide 500 micrograms
Study: 1619006
Drug: Subcutaneous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous octreotide 100 micrograms
Study: 1619006
Drug: Intranasal octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal octreotide (all doses)
Study: 6095549
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg/die
Study: 6095549
Drug: Cimetidine 2000
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 2000 mg/die
Study: 6095549
Drug: Cimetidine 2000
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 2000 mg/die + Pirenzepine 2 X 10 mg/die
Study: 27139523
Drug: Reduced-intensity treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-intensity treatment with liberalized goals for serum phosphorus and parathyroid hormone (PTH)
Study: 12876240
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (Rebif) treatment
Study: 1906432
Drug: Cibenzoline (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline (260 mg/day and 320 mg/day)
Study: 1906432
Drug: Flecainide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (200 mg/day and 300 mg/day)
Study: 1906432
Drug: Flecainide (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (long-term treatment after conversion)
Study: 1906432
Drug: Cibenzoline (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline (long-term treatment after conversion)
Study: 31162588
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNSs) to pregnant women until 6 mo postpartum and child LNSs from 6-24 mo of age (LNS-LNS)
Study: 31162588
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid (IFA) and no child supplement (IFA-Control)
Study: 29199503
Drug: SMART Arm
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART Arm with outcome-triggered electrical stimulation and usual therapy
Study: 29199503
Drug: SMART Arm
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART Arm alone and usual therapy
Study: 29199503
Drug: usual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: usual therapy
Study: 24934070
Drug: Diet soda
Normalized name: Magadi soda
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet soda (200 ml with aspartame and acesulfame potassium)
Study: 24934070
Drug: Regular soda
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular soda (200 ml without sweetener)
Study: 773301
Drug: Intravenous gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gentamicin by bolus administration (3 to 5 min)
Study: 773301
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion of gentamicin (2 h)
Study: 31583436
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg twice daily with chemotherapy
Study: 31583436
Drug: Metformin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin with chemotherapy
Study: 23726373
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg ghrelin
Study: 21366475
Drug: Long-acting injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injectable risperidone (25 to 50 mg every two weeks)
Study: 21366475
Drug: Oral antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotics (psychiatrist's choice)
Study: 19695629
Drug: Active transcutaneous
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active transcutaneous electrical nerve stimulation for 4 weeks (2 hours daily)
Study: 19695629
Drug: Sham transcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham transcutaneous electrical nerve stimulation for 4 weeks (2 hours daily)
Study: 9392698
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg twice a day)